目的探討趨化因子受體CXCR4和CCR7在甲狀腺癌中的表達(dá)及其臨床病理意義。方法選取2006~2009年期間在我院行手術(shù)治療的甲狀腺癌患者55例和2009年在我院行手術(shù)治療的甲狀腺腺瘤患者30例,采用免疫組織化學(xué)染色SP法檢測甲狀腺癌及甲狀腺腺瘤組織中的CXCR4和CCR7的表達(dá)。結(jié)果CXCR4和CCR7在甲狀腺癌中的表達(dá)陽性率均明顯高于甲狀腺腺瘤(P lt;0.01)。CXCR4和CCR7在臨床分期為Ⅲ+Ⅳ期的甲狀腺癌患者中的表達(dá)陽性率均明顯高于臨床分期為Ⅰ+Ⅱ期者(P lt;0.05); CCR7在有淋巴結(jié)轉(zhuǎn)移的甲狀腺癌中的表達(dá)陽性率明顯高于無淋巴結(jié)轉(zhuǎn)移者(P lt;0.05),而CXCR4的表達(dá)陽性率與甲狀腺癌患者有無淋巴結(jié)轉(zhuǎn)移無關(guān)(P gt;0.05); CXCR4和CCR7在甲狀腺癌組織中的表達(dá)陽性率與甲狀腺癌患者的年齡和性別均無關(guān)(P gt;0.05)。在甲狀腺癌中,CXCR4陽性表達(dá)和CCR7陽性表達(dá)呈正相關(guān)(rs=0.491,P=0.000)。結(jié)論CXCR4和CCR7協(xié)同參與了甲狀腺癌的進(jìn)展,可作為判斷甲狀腺癌預(yù)后的指標(biāo); CCR7高表達(dá)提示甲狀腺癌容易發(fā)生淋巴結(jié)轉(zhuǎn)移。
引用本文: 熊斌,王崇樹. 趨化因子受體CXCR4和CCR7在甲狀腺癌中的表達(dá)及其臨床病理意義. 中國普外基礎(chǔ)與臨床雜志, 2011, 18(12): 1301-1304. doi: 復(fù)制
版權(quán)信息: ?四川大學(xué)華西醫(yī)院華西期刊社《中國普外基礎(chǔ)與臨床雜志》版權(quán)所有,未經(jīng)授權(quán)不得轉(zhuǎn)載、改編
1. | Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis [J]. Nature, 2001, 410(6824): 5056. |
2. | 蔡偉, 劉丹丹, 康驊, 等. ET方案新輔助化療對乳腺癌組織中CXCR4表達(dá)的影響及臨床意義 [J]. 中國普外基礎(chǔ)與臨床雜志, 2010, 17(8): 812815, 823. |
3. | 邱明遠(yuǎn), 李健文, 鄭民華. CXCR4和CCR7在腫瘤中的進(jìn)展研究 [J]. 中國癌癥雜志, 2010, 20(30): 222226. |
4. | 熊斌, 王崇樹. SDF1/CXCR4及CCL19/21CCR7與腫瘤的關(guān)系 [J]. 腫瘤預(yù)防與治療, 2011, 24(2): 131133. |
5. | Spierings DC, de Vries EG, Vellenga E, et al. Tissue distribution of the death ligand TRAIL and its receptors [J]. J Histochem Cytochem, 2004, 52(6): 821831. |
6. | Yasuoka H, Kodama R, Hirokawa M, et al. CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis [J]. BMC Cancer, 2008, 8: 274282. |
7. | 關(guān)海霞, 單忠艷, 米小軼, 等. 普遍食鹽碘化前后甲狀腺癌發(fā)病變化的11年病理資料分析 [J]. 中國醫(yī)科大學(xué)學(xué)報(bào), 2006, 35(3): 284285. |
8. | 劉小華, 張敬杉, 陳金劍, 等. 甲狀腺乳頭狀癌中央?yún)^(qū)淋巴結(jié)清掃術(shù)臨床分析 [J]. 湖南醫(yī)學(xué), 2010, 21(20): 5859. |
9. | 沈強(qiáng). 甲狀腺癌頸淋巴結(jié)清掃術(shù)的幾點(diǎn)看法 [J]. 外科理論與實(shí)踐, 2009, 14(4): 379381. |
10. | Torregrossa L, Faviana P, Filice ME, et al. CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin3 and Hector battifora mesothelial cell1 [J]. Thyroid, 2010, 20(5): 495504. |
11. | 蔚青, 金曉龍, 葉蕾, 等. IL13和CXCR4在甲狀腺乳頭狀癌中的表達(dá)及其相關(guān)性 [J]. 中華內(nèi)分泌外科雜志, 2010, 4(2): 7375. |
12. | Li YM, Pan Y, Wei Y, et al. Upregulation of CXCR4 is essential for HER2mediated tumor metastasis [J]. Cancer Cell, 2004, 6(5): 459469. |
13. | Sutton A, Friand V, BruléDonneger S, et al. Stromal cellderived factor1/chemokine (CXC motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion [J]. Mol Cancer Res, 2007, 5(1): 2133. |
14. | Castellone MD, Guarino V, De Falco V, et al. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas [J]. Oncogene, 2004, 23(35): 59585967. |
15. | Till KJ, Lin K, Zuzel M, et al. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes [J]. Blood, 2002, 99(8): 29772984. |
16. | Ghobrial IM, Bone ND, Stenson MJ, et al. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in Bcell chronic lymphocytic leukemia/ small lymphocytic lymphoma [J]. Mayo Clin Proc, 2004, 79(3): 318325. |
17. | 馬飛, 寧力, 張穎妹, 等. 趨化因子受體CCR7促進(jìn)乳腺癌細(xì)胞的趨化與侵襲 [J]. 第四軍醫(yī)大學(xué)學(xué)報(bào), 2004, 25(20): 18831886. |
18. | Liu Y, Ji R, Li J, et al. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis [J]. J Exp Clin Cancer Res, 2010, 29: 16. |
19. | Wagner PL, Moo TA, Arora N, et al. The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma [J]. Ann Surg Oncol, 2008, 15(10): 28332841. |
20. | González HE, Leiva A, Tobar H, et al. Altered chemokine receptor expression in papillary thyroid cancer [J]. Thyroid, 2009, 19(9): 957965. |
21. | 寶榮, 王佾, 張薇, 等. 甲狀腺乳頭狀癌中趨化因子受體CCR7的表達(dá) [J]. 第三軍醫(yī)大學(xué)學(xué)報(bào), 2010, 32(14): 15861587. |
22. | 王明華, 黃鐵柱, 惠震, 等. 趨化因子受體CXCR4在甲狀腺癌中的表達(dá) [J]. 腫瘤防治雜志, 2008, 35(2): 107109. |
23. | Cabioglu N , Yazici M S, Arun B, et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer [J]. Clin Cancer Res, 2005,11(16): 56865693. |
- 1. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis [J]. Nature, 2001, 410(6824): 5056.
- 2. 蔡偉, 劉丹丹, 康驊, 等. ET方案新輔助化療對乳腺癌組織中CXCR4表達(dá)的影響及臨床意義 [J]. 中國普外基礎(chǔ)與臨床雜志, 2010, 17(8): 812815, 823.
- 3. 邱明遠(yuǎn), 李健文, 鄭民華. CXCR4和CCR7在腫瘤中的進(jìn)展研究 [J]. 中國癌癥雜志, 2010, 20(30): 222226.
- 4. 熊斌, 王崇樹. SDF1/CXCR4及CCL19/21CCR7與腫瘤的關(guān)系 [J]. 腫瘤預(yù)防與治療, 2011, 24(2): 131133.
- 5. Spierings DC, de Vries EG, Vellenga E, et al. Tissue distribution of the death ligand TRAIL and its receptors [J]. J Histochem Cytochem, 2004, 52(6): 821831.
- 6. Yasuoka H, Kodama R, Hirokawa M, et al. CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis [J]. BMC Cancer, 2008, 8: 274282.
- 7. 關(guān)海霞, 單忠艷, 米小軼, 等. 普遍食鹽碘化前后甲狀腺癌發(fā)病變化的11年病理資料分析 [J]. 中國醫(yī)科大學(xué)學(xué)報(bào), 2006, 35(3): 284285.
- 8. 劉小華, 張敬杉, 陳金劍, 等. 甲狀腺乳頭狀癌中央?yún)^(qū)淋巴結(jié)清掃術(shù)臨床分析 [J]. 湖南醫(yī)學(xué), 2010, 21(20): 5859.
- 9. 沈強(qiáng). 甲狀腺癌頸淋巴結(jié)清掃術(shù)的幾點(diǎn)看法 [J]. 外科理論與實(shí)踐, 2009, 14(4): 379381.
- 10. Torregrossa L, Faviana P, Filice ME, et al. CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin3 and Hector battifora mesothelial cell1 [J]. Thyroid, 2010, 20(5): 495504.
- 11. 蔚青, 金曉龍, 葉蕾, 等. IL13和CXCR4在甲狀腺乳頭狀癌中的表達(dá)及其相關(guān)性 [J]. 中華內(nèi)分泌外科雜志, 2010, 4(2): 7375.
- 12. Li YM, Pan Y, Wei Y, et al. Upregulation of CXCR4 is essential for HER2mediated tumor metastasis [J]. Cancer Cell, 2004, 6(5): 459469.
- 13. Sutton A, Friand V, BruléDonneger S, et al. Stromal cellderived factor1/chemokine (CXC motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion [J]. Mol Cancer Res, 2007, 5(1): 2133.
- 14. Castellone MD, Guarino V, De Falco V, et al. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas [J]. Oncogene, 2004, 23(35): 59585967.
- 15. Till KJ, Lin K, Zuzel M, et al. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes [J]. Blood, 2002, 99(8): 29772984.
- 16. Ghobrial IM, Bone ND, Stenson MJ, et al. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in Bcell chronic lymphocytic leukemia/ small lymphocytic lymphoma [J]. Mayo Clin Proc, 2004, 79(3): 318325.
- 17. 馬飛, 寧力, 張穎妹, 等. 趨化因子受體CCR7促進(jìn)乳腺癌細(xì)胞的趨化與侵襲 [J]. 第四軍醫(yī)大學(xué)學(xué)報(bào), 2004, 25(20): 18831886.
- 18. Liu Y, Ji R, Li J, et al. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis [J]. J Exp Clin Cancer Res, 2010, 29: 16.
- 19. Wagner PL, Moo TA, Arora N, et al. The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma [J]. Ann Surg Oncol, 2008, 15(10): 28332841.
- 20. González HE, Leiva A, Tobar H, et al. Altered chemokine receptor expression in papillary thyroid cancer [J]. Thyroid, 2009, 19(9): 957965.
- 21. 寶榮, 王佾, 張薇, 等. 甲狀腺乳頭狀癌中趨化因子受體CCR7的表達(dá) [J]. 第三軍醫(yī)大學(xué)學(xué)報(bào), 2010, 32(14): 15861587.
- 22. 王明華, 黃鐵柱, 惠震, 等. 趨化因子受體CXCR4在甲狀腺癌中的表達(dá) [J]. 腫瘤防治雜志, 2008, 35(2): 107109.
- 23. Cabioglu N , Yazici M S, Arun B, et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer [J]. Clin Cancer Res, 2005,11(16): 56865693.